Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Personalized Medicine|May 24, 2018
Is it prime time for personalized medicine in cancer treatment?Patricia S Kho, Wei Chua, Melissa M Moore, et al.
Current Opinion in Molecular Therapeutics|January 15, 2010
Predictive biomarkers of clinical response to targeted antibodies in colorectal cancerWei Chua, Melissa M Moore, Kellie A Charles, et al.
Health Communication|January 8, 2019
Restorative Narratives for Health PromotionKaitlin Fitzgerald, Elaine Paravati, Melanie C Green, et al.
Critical Reviews in Oncology/Hematology|August 20, 2010
Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancerWei Chua, Patricia S Kho, Melissa M Moore, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 1, 2009
Ethnic differences in drug metabolism and toxicity from chemotherapyViet Hong Phan, Melissa M Moore, Andrew J McLachlan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 26, 2017
A qualitative evaluation of breast cancer survivors' acceptance of and preferences for consumer wearable technology activity trackersNga H Nguyen, Nyssa T Hadgraft, Melissa M Moore, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2014
The clinical relevance of pathologic subtypes in metastatic lung adenocarcinomaTimothy D Clay, Hongdo Do, Vijaya Sundararajan, et al.
Australian and New Zealand Journal of Public Health|July 9, 2025
Cancer control measures have prevented 230,000 deaths in Australia since the mid-1980sBrigid M Lynch, Matthew T Warkentin, Melissa M Moore, et al.
Pathology|December 5, 2013
EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinomaPrudence A Russell, Yong Yu, Hongdo Do, et al.
Medical Oncology (Northwood, London, England)|September 8, 2017
EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinomaTimothy D Clay, Prudence A Russell, Hongdo Do, et al.
Pageof 3